Gastroenterology, GI Surgery and Liver Diseases Specialty Report 2021
We launched a database called SECURE-IBD that has already yielded the insight that TNF antagonists appear to be a low-risk IBD therapy where COVID-19 is concerned, and another study, called ICARUS, intended to explore the seroprevalence of COVID-19 using blood samples regularly collected from IBD patients during infusion therapy. We also repurposed wearable technology originally developed for IBD to monitor our staff for both COVID-19 infection and pandemic-related stress.
